Special Issue

Stimuli-Responsive Polymeric Nanoparticles for the Treatment of Metabolic and Neurodegenerative Diseases

Message from the Guest Editor

Recent advances in nanomedicine have demonstrated the immense potential of nanoparticles in managing metabolic disorders and neurodegenerative diseases. Nanoparticles address challenges such as unspecific site targeting and uncontrolled drug release while offering innovative solutions for delivering therapeutics to the central nervous system by overcoming the bloodbrain barrier. Among these approaches, stimuliresponsive polymeric nanoparticles stand out for their significant potential and versatility. These nanoparticles are engineered to control drug release by responding to naturally occurring or externally applied stimuli, enabling precise drug release in specific organs or regions, thereby enhancing therapeutic effectiveness. Consequently, there is a growing need to develop nanoparticles with the ability to target specific organs, cross the blood-brain barrier, deliver therapeutic agents, diagnose or monitor disease progression, and modulate metabolic disorders and neurodegenerative diseases. In this Special Issue, we invite authors to submit original research and review articles exploring the latest advances in stimuli-responsive polymeric nanoparticles.

Guest Editor

Dr. Jialiu Zena

Department of Biomedical and Chemical Engineering, Syracuse University, Syracuse, NY 13244, USA

Deadline for manuscript submissions

closed (25 March 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/214568

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

